Baidu
map

诺和诺德(Novo Nordisk)糖尿病药物Victoza优于默沙东公司药物Januvia

2012-04-16 potato 生物谷

2012年4月6日,丹麦诺和诺德(Novo Nordisk)公司,世界最大的胰岛素生产商,周五在一份声明中称,其糖尿病药物Victoza产品标签更新申请已获美国FDA批准,该标签更新所包含的数据表明,在血糖水平控制及体重降低方面,Victoza比默沙东(Merck & Co)公司糖尿病药物Januvia更具优势。 来自一项为期26周的开放标签临床试验数据表明,与接受Januvia 100

2012年4月6日,丹麦诺和诺德(Novo Nordisk)公司,世界最大的胰岛素生产商,周五在一份声明中称,其糖尿病药物Victoza产品标签更新申请已获美国FDA批准,该标签更新所包含的数据表明,在血糖水平控制及体重降低方面,Victoza比默沙东(Merck & Co)公司糖尿病药物Januvia更具优势。

来自一项为期26周的开放标签临床试验数据表明,与接受Januvia 100mg片剂治疗的患者组相比,接受1.2mg及1.8mg Victoza治疗的患者组其血糖水平及体重都得到了更大幅度的降低,诺和诺德公司在声明中称。

"这些研究的数据进一步证明了Victoza强大的临床特性及在II型糖尿病治疗中的价值,"首席科学官Mads Krogsgaard Thomsen在声明中称。(生物谷bioon.com)

编译自:Routers
http://www.reuters.com/article/2012/04/06/us-novonordisk-idUSBRE8350IQ20120406

相关阅读

糖尿病药Victoza疗效优于Januvia

新型降糖药Victoza今年一季度创市场佳绩

诺和诺德:胰岛素守望者

糖尿病治疗市场龙虎斗

欧盟批准缓释艾塞那肽用于糖尿病治疗

未来10年胰岛素替代疗法将继续统治市场
重大疾病治疗领域最具价值新药汇总

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1862734, encodeId=48141862e3406, content=<a href='/topic/show?id=0b69542242' target=_blank style='color:#2F92EE;'>#CTO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5422, encryptionId=0b69542242, topicName=CTO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c66088, createdName=gao_jian4217, createdTime=Fri Oct 05 05:51:00 CST 2012, time=2012-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2011770, encodeId=80532011e7027, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Thu Sep 27 05:51:00 CST 2012, time=2012-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1259880, encodeId=9f35125988050, content=<a href='/topic/show?id=6ff910336054' target=_blank style='color:#2F92EE;'>#默沙东#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103360, encryptionId=6ff910336054, topicName=默沙东)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=28d456, createdName=yese, createdTime=Wed Apr 18 11:51:00 CST 2012, time=2012-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1584039, encodeId=811f158403969, content=<a href='/topic/show?id=1f13e6767e9' target=_blank style='color:#2F92EE;'>#糖尿病药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76767, encryptionId=1f13e6767e9, topicName=糖尿病药物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5edb17003695, createdName=minhuang75_72521589, createdTime=Wed Apr 18 11:51:00 CST 2012, time=2012-04-18, status=1, ipAttribution=)]
    2012-10-05 gao_jian4217
  2. [GetPortalCommentsPageByObjectIdResponse(id=1862734, encodeId=48141862e3406, content=<a href='/topic/show?id=0b69542242' target=_blank style='color:#2F92EE;'>#CTO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5422, encryptionId=0b69542242, topicName=CTO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c66088, createdName=gao_jian4217, createdTime=Fri Oct 05 05:51:00 CST 2012, time=2012-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2011770, encodeId=80532011e7027, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Thu Sep 27 05:51:00 CST 2012, time=2012-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1259880, encodeId=9f35125988050, content=<a href='/topic/show?id=6ff910336054' target=_blank style='color:#2F92EE;'>#默沙东#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103360, encryptionId=6ff910336054, topicName=默沙东)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=28d456, createdName=yese, createdTime=Wed Apr 18 11:51:00 CST 2012, time=2012-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1584039, encodeId=811f158403969, content=<a href='/topic/show?id=1f13e6767e9' target=_blank style='color:#2F92EE;'>#糖尿病药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76767, encryptionId=1f13e6767e9, topicName=糖尿病药物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5edb17003695, createdName=minhuang75_72521589, createdTime=Wed Apr 18 11:51:00 CST 2012, time=2012-04-18, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1862734, encodeId=48141862e3406, content=<a href='/topic/show?id=0b69542242' target=_blank style='color:#2F92EE;'>#CTO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5422, encryptionId=0b69542242, topicName=CTO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c66088, createdName=gao_jian4217, createdTime=Fri Oct 05 05:51:00 CST 2012, time=2012-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2011770, encodeId=80532011e7027, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Thu Sep 27 05:51:00 CST 2012, time=2012-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1259880, encodeId=9f35125988050, content=<a href='/topic/show?id=6ff910336054' target=_blank style='color:#2F92EE;'>#默沙东#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103360, encryptionId=6ff910336054, topicName=默沙东)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=28d456, createdName=yese, createdTime=Wed Apr 18 11:51:00 CST 2012, time=2012-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1584039, encodeId=811f158403969, content=<a href='/topic/show?id=1f13e6767e9' target=_blank style='color:#2F92EE;'>#糖尿病药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76767, encryptionId=1f13e6767e9, topicName=糖尿病药物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5edb17003695, createdName=minhuang75_72521589, createdTime=Wed Apr 18 11:51:00 CST 2012, time=2012-04-18, status=1, ipAttribution=)]
    2012-04-18 yese
  4. [GetPortalCommentsPageByObjectIdResponse(id=1862734, encodeId=48141862e3406, content=<a href='/topic/show?id=0b69542242' target=_blank style='color:#2F92EE;'>#CTO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5422, encryptionId=0b69542242, topicName=CTO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c66088, createdName=gao_jian4217, createdTime=Fri Oct 05 05:51:00 CST 2012, time=2012-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2011770, encodeId=80532011e7027, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Thu Sep 27 05:51:00 CST 2012, time=2012-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1259880, encodeId=9f35125988050, content=<a href='/topic/show?id=6ff910336054' target=_blank style='color:#2F92EE;'>#默沙东#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103360, encryptionId=6ff910336054, topicName=默沙东)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=28d456, createdName=yese, createdTime=Wed Apr 18 11:51:00 CST 2012, time=2012-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1584039, encodeId=811f158403969, content=<a href='/topic/show?id=1f13e6767e9' target=_blank style='color:#2F92EE;'>#糖尿病药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76767, encryptionId=1f13e6767e9, topicName=糖尿病药物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5edb17003695, createdName=minhuang75_72521589, createdTime=Wed Apr 18 11:51:00 CST 2012, time=2012-04-18, status=1, ipAttribution=)]

相关资讯

赛诺菲抗癌药Zaltrap 前列腺癌III期研究败北

2012年4月5日,赛诺菲(Sanofi)公司和Regeneron制药公司今天宣布,其合作开发的抗癌药物Zaltrap(也称aflibercept)在一项关于前列腺癌治疗的III期研究中未达到预期目标,不过,美国当局正在审查该药用于结肠癌的治疗。 去年12月,Regeneron公司称,赛诺菲公司已撤回有关抗癌药Zalrap的上市审批申请,并计划在今年年初重新提交。 "该项III期研究未达到改善

诺华COPD药物QVA149 首批3项III期研究达主要目标

2012年4月2日,瑞士制药巨头诺华(Novartis)公司周一宣布,有关QVA149治疗慢性阻塞性肺病(chronic obstructive pulmonary disease,COPD)的首批3项III期研究均达到了预期的主要目标。 QVA149,一种具双重作用模式的支气管扩张剂,是诺华公司在其Breezhaler单剂量干粉吸入器中的第三个创新药物。 诺华公司称,SHINE、BRIGHT

安进公司新型肺癌药物motesanib III期研究结果令人失望

2012年4月1日,安进(Amgen)公司肺癌药物motesanib在III期研究中没有达到预期主要目标。 该药由安进公司与武田(Takeda)制药旗下Millennium公司联合开发。在III期研究中,motesanib结合2种化疗药物,未能延长晚期非鳞状非小细胞肺癌(advanced non-squamous non-small cell lung cancer,NSCLC)患者总体存活时间

葛兰素史克HIV新药dolutegravir与默沙东药物Isentress 匹敌

2012年4月2日,路透社报道,由葛兰素史克(GlaxoSmithKline)公司和日本盐野义(Shionogi)公司合作开发的一种新HIV/AIDS药物dolutegravir,在III临床试验中达到了与默沙东(Merck & Co)HIV/AIDS药物Isentress相匹敌的疗效。 Dolutegravir为日服一次,而Isentress为日服2次,这两者均为HIV整合酶的抑制剂,

Akebia公司AKB-6548治疗慢性肾病 II阶段临床结果公布

Akebia公司AKB-6548 II 阶段临床研究结果公布,AKB-6548 是一种治疗慢性肾病的药物。 II 阶段研究设置而来随机、双盲、安慰剂控制等的对照,通过42天的研究,达到了初级终末点 公司称:结果显示血红蛋白和整体血红细胞产量都有明显改善。 同安慰剂相比,AKB-6548同时有很好的耐受性,肝功能和肾功能有没有表现出与剂量相关的副作用。 AKB-6548在生物等效性上等同于缺

礼来公司阿尔茨海默氏病脑部斑块显像剂Amyvid获FDA批准

2012年4月7日,礼来(Eli Lilly)公司的一种显像剂获得美国监管机构的点头。该显像剂将首次能够帮助医生检测与阿尔茨海默氏症(Alzheimer's disease)相关的脑部斑块,该公司称。 美国FDA批准了一种被称为Amyvid的放射性染料,用于帮助医生排除患者是否患有阿尔茨海默氏症(老年痴呆症的最常见形式),礼来公司周五晚宣布道。 该染料能够与阿尔茨海默氏症患者大脑中聚集的β淀粉

Baidu
map
Baidu
map
Baidu
map